placebo Population: T2D with established CVD or high CV risk Study Objectives: Primary Endpoint: Time to first occurrence of 3-point MACE (CV death, non-fatal MI, non-fatal stroke) Secondary Endpoints: Heart failure hospitalization, all-cause mortality, kidney outcomes Anticipated Results: Expected completion 2025
For researchers focused on the interaction between neurological function, hormonal rhythms, and recovery processes, DSIP 15mg from SSP Research provides a high-purity, research-grade peptide for consistent experimental use
They improve blood flow, reduce inflammation, strengthen follicles, and help extend the active growth phase
ALA demonstrates a particular affinity for the liver, heart, and skeletal muscle
This is helpful in an athletic setting